Skip to main content
SpringerLink
Log in

Systemic and Coronary Haemodynamics and Pharmacodynamics of Enalapril and Enalaprilat in Congestive Heart Failure

  • Section 2
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Enalapril is an effective angiotensin-converting enzyme (ACE) inhibitor which produces salutary, beneficial haemodynamic effects in patients with congestive heart failure. Enalapril also produces beneficial neurohumoral changes, as well as improving abnormal coronary haemodynamics and myocardial energetics that are frequently encountered in these patients. Administration of enalapril once or twice daily appears to be quite effective during maintenance therapy in patients with chronic congestive heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ader R, Chatterjee K, Ports T, Brundage B, Hiramatsu B, et al. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by oral angiotensin converting enzyme inhibitor. Circulation 61: 931–937, 1980

    Article  PubMed  CAS  Google Scholar 

  • Brunner HR, Waeber B, Nussberger J, Schaller MD. Long term clinical experiences with enalapril in essential hypertension. Journal of Hypertension 1(Suppl. 1): 103–107, 1983

    PubMed  CAS  Google Scholar 

  • Chatterjee K, Viquerat CE, Daly P. Neurohumoral abnormalities in heart failure. Heart Failure 1: 69–83, 1985

    Google Scholar 

  • Clauser E, Gonzales MF, Bouhnik J, Corvol P, Menard J. The effects of converting enzyme inhibitors on plasma angioten-sinogen and plasma aldosterone in sodium-depleted rats. Journal of Hypertension 1(Suppl. 1): 37–40, 1983

    PubMed  CAS  Google Scholar 

  • Cody RJ. Clinical and hemodynamic experience with enalapril in congestive heart failure. American Journal of Cardiology 55: 36A–40A, 1985

    Article  PubMed  CAS  Google Scholar 

  • Creager MA, Massie BM, Faxon DP, Friedman SD, Kramer BL, et al. Acute and long term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. Journal of the American College of Cardiology 6: 163–170, 1985

    Article  PubMed  CAS  Google Scholar 

  • De Marco T, Chatterjee K, Rouleau JL, Parmley WW. Abnormal coronary hemodynamics and myocardial energetics in patients with chronic heart failure caused by ischemic heart disease and dilated cardiomyopathy. American Heart Journal 115: 809–815, 1988

    Article  PubMed  Google Scholar 

  • De Marco T, Daly PA, Liu M, Kayser S, Parmley WW, et al. Enalaprilat, a new parenteral angiotensin converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure. Journal of the American College of Cardiology 9: 1131–1138, 1987

    Article  PubMed  Google Scholar 

  • DiCarlo L, Chatterjee K, Parmley WW, Swedberg K, Atherton B, et al. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic evaluations. Journal of the American College of Cardiology 2: 865–871, 1983

    Article  PubMed  CAS  Google Scholar 

  • Dickstein K, Soyland E, Gundersten T, Abrahamsen AM, Kjekshus J. Acute and chronic hemodynamic effects of enalapril in congestive heart failure. International Journal of Cardiology 6: 445–456, 1984

    Article  PubMed  CAS  Google Scholar 

  • Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin, et al. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. American Journal of Cardiology 53: 105–108, 1984

    Article  PubMed  CAS  Google Scholar 

  • Fitz A, Lawton W, Reimer J, Nelson G. The effect of enalapril, a non-thiol converting enzyme inhibitor on vasoactive factors in hypertension. Clinical Research 30: 775A, 1982

    Google Scholar 

  • Fitzpatrick D, Nicholls MG, Ikram H, Espiner EA. Hemodynamic hormonal and electrolyte effects of enalapril in heart failure. British Heart Journal 50: 163–169, 1983

    Article  PubMed  CAS  Google Scholar 

  • Foud FM, Tarazi RC, Bravo EL, Textor SE. Hemodynamic and antihypertensive effects of the new oral angiotensin-converting enzyme inhibitor MK-421 (enalapril). Hypertension 6: 167–174, 1984

    Google Scholar 

  • Fraser AG, Henderson AH, Lewis MJ, Mulligan IP, Tirlapur VG. Acute and chronic effects of enalapril during rest and exercise in congestive heart failure. British Journal of Clinical Pharmacology 20: 263P–264P, 1985

    Google Scholar 

  • Fregly MJ, Fater DC. Effect of the angiotensin converting enzyme inhibitor MK-421 on experimentally induced drinking. Physiologist 24: 12, 1981

    Google Scholar 

  • Fruncillo RJ, Roccl Jr ML, Shepley K, Clementi RA, Derita R, et al. Enalaprilat accumulates after chronic enalapril dosing in renal failure. Clinical Pharmacology and Therapeutics 37: 197, 1985

    Google Scholar 

  • Gross DM, Sweet CS, Ulm EH, Backlund EP, Morris AA, et al. Effect of N-[(s)-l-carboxy-3-phenylpropyl]-L-ALA-L-PRO and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. Journal of Pharmacology and Experimental Therapeutics 216: 522–557, 1981

    Google Scholar 

  • Guidicelli JF, Berdeaux A, Edouard A, Richer C, Jacolot D. The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects. British Journal of Clinical Pharmacology 20: 211–218, 1985

    Article  Google Scholar 

  • Heel RC, Brogden RN, Speight TM, Avery GS. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20: 409–458, 1980

    Article  PubMed  CAS  Google Scholar 

  • Hodsman GP, Brown JJ, Cummings AMM, Davies DL, East BW, et al. Enalapril in the treatment of hypertension with renal artery stenosis. British Medical Journal 287: 1413–1417, 1983

    Article  PubMed  CAS  Google Scholar 

  • Howlett DR, Longman SD. Effects of chronic enalapril (MK-421) treatment on the renin-angiotensin system in the sodium depleted rat. British Journal of Pharmacology 79: 323, 1983

    Google Scholar 

  • Jackson B, Johnson CL. Angiotensin converting enzyme inhibition by MK421: a potent long acting oral agent. Australian and New Zealand Journal of Medicine 12: 355–360, 1984

    Google Scholar 

  • Johnston CL, Jackson BJ, Larmour I, Cubella R, Casley D. Plasma enalapril levels and hormonal effects after short and long-term administration in essential hypertension. British Journal of Clinical Pharmacology 18(Suppl. 2): 233S–239S, 1984

    Article  PubMed  Google Scholar 

  • Kelley J, Doyle G, Donohoe J, Laher M, Vandenburg MJ, et al. The pharmacokinetic profile of enalaprilat in normal subjects and patients with renal impairment. British Journal of Clinical Pharmacology 18: 274, 1984

    Google Scholar 

  • Kelley J, Doyle G, Donohoe J, Laher M, Vandenberg MJ, et al. Chronic dose pharmacokinetics of enalapril in renal impairment. British Journal of Clinical Pharmacology 20: 264–265, 1985

    Google Scholar 

  • Larochelle P, Gutkowska J, Schiffrin E, Kuchel O, Hamet P, et al. Effect of enalapril on renin, angiotensin converting enzyme activity, aldosterone and prostaglandins in patients with hypertension. Clinical and Investigative Medicine 8: 197–201, 1985

    PubMed  CAS  Google Scholar 

  • Levine TB, Oliver MT, Garberg V, Shyarkey SW, Cohn JN. Hemodynamic and clinical response to enalapril, a long-acting converting enzyme inhibitor in patients with congestive heart failure. Circulation 69: 548–553, 1984

    Article  PubMed  CAS  Google Scholar 

  • McCaa RE, Gillespie JB. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium deficient dogs. Federation Proceedings 43: 1336–1341, 1984

    PubMed  CAS  Google Scholar 

  • Odya LE, Wilgis FP, Walker JF, Oparil S. Immune reactive bradykinin and [DES-ARG9]-bradykinin in low renin essential hypertension before and after treatment with enalapril (MK421). Journal of Laboratory and Clinical Medicine 102: 714–721, 1983

    PubMed  CAS  Google Scholar 

  • Oparil S, Horton R, Wilkins LH, Irvin J, Hammett DK, et al. Antihypertensive effect of enalapril (MK421) in low renin essential hypertension: role of vasodilator prostaglandins. Clinical Research 31: 538A, 1983

    Google Scholar 

  • Ryan MJ, Boucher DM, Cohen DM, Essenburg AD, Major TC, et al. Antihypertensive effects of C1-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor. Journal of Pharmacology and Experimental Therapeutics 228: 312–318, 1984

    PubMed  CAS  Google Scholar 

  • Sanchez RA, Marco E, Gilbert HB, Raffaele P, Brito M, et al. Natriuretic effect and changes in renal hemodynamics induced by enalapril in essential hypertension. Drugs 30(Suppl. 1): 49–58, 1985

    Article  PubMed  Google Scholar 

  • Schiffrin EL, Gutkowska J, Thibault G, Genest J. Effect of enalapril (MK-421) an orally active angiotensin-I converting enzyme inhibitor, on blood pressure, active and inactive plasma renin, urinary prostaglandin-E2, and kallikrein excretion in conscious rats. Canadian Journal of Physiology and Pharmacology 62: 116–123, 1984

    Article  PubMed  CAS  Google Scholar 

  • Schwartz JB, Taylor A, Abernathy D, O’Meara M, Farmer J, et al. Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. Journal of Cardiovascular Pharmacology 7: 767–776, 1985

    Article  PubMed  CAS  Google Scholar 

  • Sweet CS, Arbegast PT, Gaul SL, Blaine EH, Gross DM. Relationship between angiotensin 1 blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats. European Journal of Pharmacology 76: 167–176, 1981

    Article  PubMed  CAS  Google Scholar 

  • Sweet LS, Ulm EH. Enalapril. In Scriabine A (Ed.) New drugs annual, cardiovascular drugs, Vol. 2, pp. 1–17, Raven Press, New York, 1984

    Google Scholar 

  • Takata Y, Di Nicolantonio R, Mendelsohn FAO, Hutchinson JS, Doyle AE. A comparison of the activity of the angiotensin converting enzyme inhibitors sq. 14225, SA 446, and MK421. Clinical and Experimental Pharmacology and Physiology 10: 131–145, 1983

    Article  PubMed  CAS  Google Scholar 

  • Till AE, Gomez HJ, Hichens M, Bolognese JA. Pharmacokinetics of repeated oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharmaceutics and Drug Disposition 5: 273–280, 1984

    Article  CAS  Google Scholar 

  • Todd PA, Heel RC. Enalapril: a review of its pharmaco-dynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31: 198–248, 1986

    Article  PubMed  CAS  Google Scholar 

  • Ulm EH, Hichens M, Gomez HJ, Till AE, Hand E, et al. Enalapril maleate and a lysing analogue (MK-521): disposition in man. British Journal of Pharmacology 14: 357–362, 1982

    Article  CAS  Google Scholar 

  • Vlasses PH, Larijani GE, Conner DP, Ferguson RK. Enalapril, a non-sulfhydryl angiotensin-converting enzyme inhibitor. Clinical Pharmacology 4: 27–40, 1985

    CAS  Google Scholar 

  • Wilkes BM. Evidence for a vasodepressor effect of the angiotensin-converting enzyme inhibitor MK421 (enalapril), independent of blockade of angiotensin II formation. Journal of Cardiovascular Pharmacology 6(6): 1036–1042, 1984

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, University of California, San Francisco, California, 94143-0124, USA

    Kanu Chatterjee & Teresa De Marco

Authors
  1. Kanu Chatterjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teresa De Marco
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chatterjee, K., De Marco, T. Systemic and Coronary Haemodynamics and Pharmacodynamics of Enalapril and Enalaprilat in Congestive Heart Failure. Drugs 39 (Suppl 4), 29–40 (1990). https://doi.org/10.2165/00003495-199000394-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199000394-00007

Keywords

Search

Navigation